Reta Weekly Research Dosing Protocol
-
For research use only. Not medical advice.
Overview
Retatrutide is typically explored in weekly ranges from 2 mg up to 12 mg, with slow escalation to manage GI load and overall tolerability. Trial-style titration stretches over 12+ weeks, with 12 mg representing the “full strength” research dose used in long-duration studies.
Weekly Titration Schedule
Weeks 1–4: Foundation Phase
Dose: 2 mg once weekly
Purpose: Establish baseline tolerability.
Notes: This lower starting dose greatly reduces initial GI events compared to starting higher.
Weeks 5–8: Low–Moderate Phase
Dose: 4 mg once weekly
Only escalate if Weeks 1–4 were well tolerated.
If GI issues appear, remain at 2 mg longer before advancing.
Weeks 9–12: High-Effect Working Phase
Dose: 8 mg once weekly
This dose produces robust metabolic effects in most research models.
If subjects struggle here, researchers commonly hold at 4 mg or alternate 4 → 6 → 8 mg with slower steps.
Week 13 and Beyond: Full-Strength Maintenance
Two common maintenance approaches:
Standard Maintenance
8 mg once weekly
Chosen for subjects requiring milder long-term effects or who experience tolerability issues at higher levels.
Maximum Maintenance (Trial-Style)
12 mg once weekly
Represents the top-end dose used in long-duration studies showing the greatest body-weight reductions.
Escalate to 12 mg only if 8 mg is stable for several weeks.
Alternate Slow Titration (For Sensitive Subjects)
If researchers want a gentler progression:
Weeks 1–4: 2 mg
Weeks 5–6: 3 mg
Weeks 7–8: 4 mg
Weeks 9–10: 6 mg
Weeks 11–12: 8 mg
Week 13+: 8–12 mg maintenance depending on tolerability
This reduces the “GI shock” some subjects experience when jumping directly 2 → 4 → 8 mg.
Frequency & Timing
Once weekly at a consistent time.
Weekly schedule matters more than exact hour.
Delayed-onset side effects (Day 3–5) are common, so avoid rapid escalation.
Cycle Length
Minimum 12 weeks to complete titration.
Full research cycles often run 24–48 weeks, especially when maintaining 8–12 mg.
Common Research Notes
Delayed side effects (itching, bile-type GI issues) may appear days after dosing; escalate cautiously.
If side effects appear during escalation, researchers typically hold or reduce the dose rather than continue upward.
Long-term stability for most subjects lands between 8–12 mg weekly, depending on goals and tolerance.
Some start at 0.5 milligrams and titrate up. Depends on the Risk profile your research is taking on.
-
.5->1->2->3->4mg, each bump per week, therefore on my 5th week now. 2mg-3mg bump gave my panda noticeable abdominal bloating/swelling/hardness/discomfort. Initiated KPV at 1mg daily sub-q below navel, relief within 24 hours, feeling normal in intestines since. 5'7" 168lbs starting point, carnivore for 2.5 years. Want to rid the visceral fat which otherwise will not go away.
There are oral BPC-157 arginate salt version capsules out there, "slow" and "fast" release versions which also further refined attenuation of this "side-effect"
Re-TAT-tra-tide SAY IT! Lol...:-)
-
I found through trial and error that 3 times per week works best for me. My kangaroo doesn't feel the "wear-off' at the end of the week when doing once per week. And I theorize that I can keep the blood serum levels higher on average without exceeding tolerable side-effects, like wanting to vomit.
Anyone have insight on why a higher peak dose once per week is more effective? Would once per day be better? -
I would encourage anyone who hasn't started Reta yet, to at least try microdosing. Benefits of saving $ and hopefully pushing any plateaus far far down the road with more titration opportunities. I am still on my 3rd week of 200mcg 3x's a week and may only go to 300mcg next week
-
yeah micro dosing is really good for some. I'm even further down the hole doing 10mg of tirz on thursdays and 2mg of survodutide on mondays. Its glorious.
@Randy im really interested in this. Do you see any differences in GI issues? I can get my insurance to pay for trizepitide, so I might be able to reduce my spend over using retatrutide.
